bpc-157 fda approval status pipeline is reviewing seven peptides this week, BPC-157, MOTS-c, and Epitalon among them. Committee meets Thursday and Friday, and the likely outcome is tighter restrictions on compounding pharmacies. Read past the headline The Peptide Craze = Big

Recent advances have introduced a bispecific molecule comprising a fully human monoclonal anti-glucose-dependent insulinotropic polypeptide receptor (GIPR) antibody conjugated to two GLP-1 analog peptides via optimized amino acid linkers

It typically strikes young adults between the ages of 20-40, most of them women

It is thought to do this by stimulating human growth receptors in injured tissue

Allergy risk to cobalt or preservatives (rare) Energy improvement: 24-72 hours Reticulocyte response: 3-5 days Neurological improvement: Weeks to months Hematological normalization: 4-8 weeks Maximum nerve repair: Up to 1 year Injection site reactions (15-20%) Mild diarrhea (initial doses) Itching/eczema (cobalt sensitivity) Transient anxiety (overstimulation) Headache (usually resolves quickly) Serious reactions are extremely rare

Car accidents, sports injuries, and falls can damage the soft tissues and joints of the cervical spine